Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | PHGDH | O43175 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL774670 | 0.89 | CXCR4 (0.42) | SIGMAR1POLBSMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL4063237 | 0.88 | CXCR4 (0.43) | SIGMAR1POLBSMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL4069045 | 0.85 | POLB (0.37) | SIGMAR1POLBSMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL4061260 | 0.83 | POLB (0.38) | SIGMAR1POLBSMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL31687741 | 0.82 | CXCR4 (0.39) | SIGMAR1POLBSMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL31265242 | 0.81 | CYP3A4 (0.40) | SIGMAR1POLBSMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL4061521 | 0.81 | MEN1 (0.41) | SIGMAR1POLBSMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL538138 | 0.81 | SIGMAR1 (0.36) | SIGMAR1POLBSMN1; SMN2CXCR4 | |
| SCHEMBL4060380 | 0.79 | — | — | |
| SCHEMBL4005712 | 0.79 | SIGMAR1 (0.35) | SIGMAR1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569691-B2 | Protected piperazino group-bearing organoxysilane compound and making method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | claimed |
| US-7569691-B2 | Protected piperazino group-bearing organoxysilane compound and making method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| EP-1714968-B1 | Protected piperazino group-bearing organoxysilane compound and making method | SHINETSU CHEMICAL CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20060241294-A1 | Protected piperazino group-bearing organoxysilane compound and making method | SHIN-ETSU CHEMICAL CO., LTD. | 2006-10-26 | — | — | US | disclosed |
| EP-1714968-A1 | Protected piperazino group-bearing organoxysilane compound and making method | Shin-Etsu Chemical Co., Ltd. (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241294-A1 | Protected piperazino group-bearing organoxysilane compound and making method | PIEZO1, VCL, VIM | SIGMAR1 1050/4885POLB 1859/4885SMN1; SMN2 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.